Manish Jain, MD
Nephrology · Columbus, INNPI 1750443297
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,200 of the $9,544 with a category attached, or 96.4%. GSK accounts for 96.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $9,264 and has fallen 99.8% since, to $19 in 2025. Among nephrology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $502.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Insmed, Inc.$95
- Fresenius USA Marketing, Inc.$53
- Vifor Pharma, Inc.$42
- AbbVie$27
- Rockwell Medical, Inc.$26
- plus $103 from 6 others
Across 9 payments — averaging $5801.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$52K
What the payments were for
- Consulting fees$9,20096%
- Food & beverage$3313%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $9,200 |
| Insmed, Inc. | 1 | $95 |
| Fresenius USA Marketing, Inc. | 3 | $53 |
| Vifor Pharma, Inc. | 3 | $42 |
| AbbVie | 2 | $27 |
| Rockwell Medical, Inc. | 2 | $26 |
| Novartis | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| Tris Pharma Inc | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
How this compares
$9,544 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcitriol | 176 | $1,293 |
| Cinacalcet Hcl | 17 | $741 |
| Tamsulosin Hcl | 21 | $400 |
| Potassium Chloride | 17 | $356 |
| Furosemide | 76 | $304 |
| Amlodipine Besylate | 69 | $222 |
| Allopurinol | 39 | $213 |
| Carvedilol | 28 | $194 |
| Lisinopril | 45 | $153 |
| Hydrochlorothiazide | 25 | $128 |
| Metoprolol Tartrate | 22 | $77 |
| Cephalexin | 14 | $62 |
| Chlorthalidone | 11 | $56 |
| Losartan Potassium | 20 | $47 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Columbus
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Jorge DiegoShelbyville$81K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.